Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort Study

The Lancet Oncology

Volumn 15, Issue 11, 2014, Pages 1215-1223

  Green, Daniel M ^a   Liu, Wei ^a   Kutteh, William H ^b,c   Ke, Raymond W ^b,c   Shelton, Kyla C ^a   Sklar, Charles A ^d   Chemaitilly, Wassim ^a   Pui, Ching Hon ^a   Klosky, James L ^a   Spunt, Sheri L ^a,e,f   Metzger, Monika L ^a,e   Srivastava, DeoKumar ^a   Ness, Kirsten K ^a   Robison, Leslie L ^a   Hudson, Melissa M ^a,e  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b Fertility Associates of Memphis   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; BUSULFAN; CARBOPLATIN; CHLORAMBUCIL; CHLORMETHINE; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; IFOSFAMIDE; PROCARBAZINE;

ADOLESCENT; ADULT; ARTICLE; AZOOSPERMIA; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CHILD; CHILDHOOD CANCER; COHORT ANALYSIS; DISEASE ASSOCIATION; DRUG EXPOSURE; HUMAN; HUMAN CELL; INFANT; MAJOR CLINICAL STUDY; MALE; OLIGOSPERMIA; PRESCHOOL CHILD; RISK FACTOR; SCHOOL CHILD; SEMEN ANALYSIS; SPERMATOGENESIS; SPERMATOZOON COUNT; SPERMATOZOON DENSITY; SPERMATOZOON MOTILITY; TREATMENT OUTCOME; YOUNG ADULT; CANCER CENTER; CHEMICALLY INDUCED; CONFIDENCE INTERVAL; DOSE RESPONSE; DRUG ADMINISTRATION; FERTILITY PRESERVATION; HOSPITAL; INCIDENCE; INFERTILITY, MALE; NEOPLASMS; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY; RISK; RISK ASSESSMENT; SURVIVOR;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; CANCER CARE FACILITIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CONFIDENCE INTERVALS; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FERTILITY PRESERVATION; HOSPITALS, PEDIATRIC; HUMANS; INCIDENCE; INFERTILITY, MALE; MALE; NEOPLASMS; ODDS RATIO; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEMEN ANALYSIS; SPERM COUNT; SURVIVORS; YOUNG ADULT;

EID: 84908119628     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70408-5     Document Type: Article

References (50)

1. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975-2010, based on November 2012 SEER data submission, posted to the SEER website accessed March, 2014. http://seer.cancer.gov/csr/1975_2010/.
2. Robison LL, Hudson MM Survivors of childhood and adolescent cancer: life-long risks and responsibilities. Nat Rev Cancer 2014, 14:61-70.
3. Green DM, Kawashima T, Stovall M, et al. Fertility of male survivors of childhood cancer. A report from the Childhood Cancer Survivor Study. J Clin Oncol 2010, 28:332-339.
4. Green DM, Nolan VG, Goodman PJ, et al. The cyclophosphamide equivalent dose as an approach for quantifying alkylating agent exposure. A report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2014, 61:53-67.
5. Ojha RP, Oancea SC, Ness KK, et al. Assessment of potential bias from non-participation in a dynamic clinical cohort of long-term childhood cancer survivors: results from the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 2013, 60:856-864.
6. Hudson MM, Ness KK, Nolan VG, et al. Prospective medical assessment of adults surviving childhood cancer: study design, cohort characteristics, and feasibility of the St. Jude Lifetime Cohort Study. Pediatr Blood Cancer 2011, 56:825-836.
7. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers Children's Oncology Group, accessed March, 2014. http://www.survivorshipguidelines.org/pdf/LTFUGuidelines.pdf.
8. Robison LL, Mertens AC, Boice JD, et al. Study design and cohort characteristics of the Childhood Cancer Survivor Study: a multi-institutional collaborative project. Med Pediatr Oncol 2002, 38:229-239.
9. WHO laboratory manual for the examination and processing of human semen 2010, Department of Reproductive Health and Research, WHOWHO, World Health Organization, Geneva. 5th edn.
10. Comhaire FH, Vermeulen L, Hinting A, Schoonjans F Accuracy of sperm characteristics in predicting the in vitro fertilizing capacity of semen. J In Vitro Fert Embryo Transf 1988, 5:326-331.
11. Bollendorf A, Check JH, Lurie D Evaluation of the effect of the absence of sperm with rapid and linear progressive motility on subsequent pregnancy rates following intrauterine insemination or in vitro fertilization. J Androl 1996, 17:550-557.
12. 2. J Stat Plan Inference 1997, 59:61-78.
13. Kenney LB, Cohen LE, Shnorhavorian M, et al. Male reproductive health after childhood, adolescent, and young adult cancer: a report from the Children's Oncology Group. J Clin Oncol 2012, 30:3408-3416.
14. Kremer LC, Mulder RL, Oeffinger KC, et al. A worldwide collaboration to harmonize guidelines for the long-term follow-up of childhood and young adult cancer survivors: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Pediatr Blood Cancer 2013, 60:543-549.
15. Chapman RM, Sutcliffe SB, Malpas JS Male gonadal dysfunction in Hodgkin's disease. JAMA 1981, 245:1323-1328.
16. Chapman RM, Rees LH, Sutcliffe SB, Edwards CRW, Malpas JS Cyclical combination chemotherapy and gonadal function. Lancet 1979, 1:285-289.
17. da Cunha MF, Meistrich ML, Fuller LM, et al. Recovery of spermatogenesis after treatment for Hodgkin's disease: limiting dose of MOPP chemotherapy. J Clin Oncol 1984, 2:571. 557.
18. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of MOPP vs ABVD. Eur J Cancer Clin Oncol 1985, 21:601-605.
19. Kenney LB, Laufer MR, Grant FD, Grier H, Diller L High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood. Cancer 2001, 91:613-621.
20. Garolla A, Pizzato C, Ferlin A, Carli MO, Selice R, Foresta C Progress in the development of childhood cancer therapy. Reprod Toxicol 2006, 22:126-132.
21. Romerius P, Stahl O, Moell C, et al. High risk of azoospermia in men treated for childhood cancer. Int J Androl 2011, 34:69-76.
22. Rendtorff R, Hohmann C, Reinmuth S, et al. Hormone and sperm analyses after chemo- and radiotherapy in childhood and adolescence. Klin Padiatr 2010, 222:145-149.
23. Thomson AB, Campbell AJ, Irvine DC, Anderson RA, Kelnar CJ, Wallace WH Semen quality and spermatozoal DNA integrity in survivors of childhood cancer: a case-control study. Lancet 2002, 360:361-367.
24. van Casteren NJ, van der Linden GH, Hakvoort-Cammel FG, Hahlen K, Dohle GR, van den Heuvel-Eibrink MM Effect of childhood cancer treatment on fertility markers in adult male long-term survivors. Pediatr Blood Cancer 2009, 52:108-112.
25. Jahnukainen K, Heikkinen R, Henriksson M, Cooper TG, Puukko-Viertomies LR, Makitie O Semen quality and fertility in adult long-term survivors of childhood acute lymphoblastic leukemia. Fertil Steril 2011, 96:837-842.
26. Wallace WH, Shalet SM, Lendon M, Morris-Jones PH Male fertility in long-term survivors of childhood acute lymphoblastic leukaemia. Int J Androl 1991, 14:312-319.
27. Jensen TK, Andersson AM, Hjollund NH, et al. Inhibin B as a serum marker of spermatogenesis: correlation to differences in sperm concentration and follicle-stimulating hormone levels. A study of 349 Danish men. J Clin Endocrinol Metab 1997, 82:4059-4063.
28. Willott GM Frequency of azoospermia. Forensic Sci Int 1982, 20:9-10.
29. Longhi A, Macchiagodena M, Vitali G, Bacci G Fertility in male patients treated with neoadjuvant chemotherapy for osteosarcoma. J Pediatr Hematol Oncol 2003, 25:292-296.
30. Petersen PM, Hansen SW, Giwercman A, Rorth M, Skakkebaek NE Dose-dependent impairment of testicular function in patients treated with cisplatin-based chemotherapy for germ cell cancer. Ann Oncol 1994, 5:355-358.
31. Brydoy M, Fossa SD, Klepp O, et al. Sperm counts and endocrinological markers of spermatogenesis in long-term survivors of testicular cancer. Br J Cancer 2012, 107:1833-1839.
32. Reinmuth S, Hohmann C, Rendtorff R, et al. Impact of chemotherapy and radiotherapy in childhood on fertility in adulthood: the FeCt-survey of childhood cancer survivors in Germany. J Cancer Res Clin Oncol 2013, 139:2071-2078.
33. Bujan L, Walschaerts M, Moinard N, et al. Impact of chemotherapy and radiotherapy for testicular germ cell tumors on spermatogenesis and sperm DNA: a multicenter prospective study from the CECOS network. Fertil Steril 2013, 100:673-680.
34. Aston KI, Krausz C, Laface I, Ruiz-Castane E, Carrell DT Evaluation of 172 candidate polymorphisms for association with oligozoospermia or azoospermia in a large cohort of men of European descent. Hum Reprod 2010, 25:1383-1397.
35. Aston KI, Carrell DT Genome-wide study of single-nucleotide polymorphisms associated with azoospermia and severe oligozoospermia. J Androl 2009, 30:711-725.
36. Romerius P, Giwercman A, Moell C, et al. Estrogen receptor alpha single nucleotide polymorphism modifies the risk of azoospermia in childhood cancer survivors. Pharmacogenet Genomics 2011, 21:263-269.
37. Pinto N, Ludeman SM, Dolan ME Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics 2009, 10:1897-1903.
38. Eggert-Kruse W, Schwarz H, Rohr G, Demirakca T, Tilgen W, Runnebaum B Sperm morphology assessment using strict criteria and male fertility under in-vivo conditions of conception. Hum Reprod 1996, 11:139-146.
39. van der Merwe FH, Kruger TF, Oehninger SC, Lombard CJ The use of semen parameters to identify the subfertile male in the general population. Gynecol Obstet Invest 2005, 59:86-91.
40. Zinaman MJ, Brown CC, Selevan SG, Clegg ED Semen quality and human fertility: a prospective study with healthy couples. J Androl 2000, 21:145-153.
41. Jouannet P, Ducot B, Feneux D, Spira A Male factors and the likelihood of pregnancy in infertile couples. I. Study of sperm characteristics. Int J Androl 1988, 11:379-394.
42. Larsen L, Scheike T, Jensen TK, et al. Computer-assisted semen analysis parameters as predictors for fertility of men from the general population. The Danish First Pregnancy Planner Study Team. Hum Reprod 2000, 15:1562-1567.
43. Meistrich ML, Finch M, da Cunha MF, Hacker U, Au WW Damaging effects of fourteen chemotherapeutic drugs on mouse testis cells. Cancer Res 1982, 42:122-131.
44. Meistrich ML, Chawla SP, Da Cunha MF, et al. Recovery of sperm production after chemotherapy for osteosarcoma. Cancer 1989, 63:2115-2123.
45. Meistrich ML, Wilson G, Mathur K, et al. Rapid recovery of spermatogenesis after mitoxantrone, vincristine, vinblastine, and prednisone chemotherapy for Hodgkin's disease. J Clin Oncol 1997, 15:3488-3495.
46. Hill M, Milan S, Cunningham D, et al. Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity. J Clin Oncol 1995, 13:387-395.
47. Green DM, Zhu L, Zhang N, et al. Lack of specificity of plasma concentrations of inhibin B and follicle-stimulating hormone for identification of azoospermic survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. J Clin Oncol 2013, 31:1324-1328.
48. Green DM, Kun LE, Matthay KK, et al. Relevance of historical therapeutic approaches to the contemporary treatment of pediatric solid tumors. Pediatr Blood Cancer 2013, 60:1083-1094.
49. Hudson MM, Neglia JP, Woods WG, et al. Lessons from the past: opportunities to improve childhood cancer survivor care through outcomes investigations of historical therapeutic approaches for pediatric hematological malignancies. Pediatr Blood Cancer 2012, 58:334-343.
50. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006, 24:2917-2931.